Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
2.
In Vivo ; 29(5): 529-31, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26359410

RESUMO

Acute pancreatitis can be attributed to numerous potential causes, such as alcohol abuse, chololithiasis, infection, lesions, tumors, hypercalcemia, hyperlipidemia, and medications. Among psychotropic medications, the use of some atypical antipsychotics, such as clozapine, olanzapine, quetiapine and risperidone, has been implicated in the development of acute pancreatitis, although the underlying mechanism has not been clarified. We describe the case of a young man with no other major medical problems, alcohol abuse or predisposing factors, who developed acute necrotizing pancreatitis following olanzapine administration, possibly through severe elevation of serum triglycerides. A pharmacogenomic analysis revealed the presence of the 5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled (HTR2C) -759C genotype which is related to increased risk for metabolic syndrome.


Assuntos
Alelos , Antipsicóticos/efeitos adversos , Benzodiazepinas/efeitos adversos , Haplótipos , Pancreatite Necrosante Aguda/etiologia , Polimorfismo de Nucleotídeo Único , Receptor 5-HT2C de Serotonina/genética , Antipsicóticos/uso terapêutico , Benzodiazepinas/uso terapêutico , Substituição de Medicamentos , Humanos , Masculino , Olanzapina , Pancreatite Necrosante Aguda/diagnóstico , Esquizofrenia/complicações , Esquizofrenia/tratamento farmacológico , Resultado do Tratamento , Adulto Jovem
3.
Am J Case Rep ; 13: 244-6, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-23569539

RESUMO

BACKGROUND: Retroperitoneal schwannomas are very rare and are usually found incidentally. CASES REPORT: Two rare cases of retroperitoneal schwannomas are reported. Both were incidentally found during US scans for non-specific epigastric pain and were initially diagnosed as non-secreting retroperitoneal tumors. The diagnosis was confirmed by CT scan. In both patients the tumors were resected. The definitive diagnosis was possible by histopathology. CONCLUSIONS: Although the preoperative assessment of a retroperitoneal tumor may be indicative of a retroperitoneal schwannoma, the definitive diagnosis is possible only by histopathology after surgical removal of the tumor.

4.
Am J Case Rep ; 13: 262-4, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-23569544

RESUMO

BACKGROUND: Multicystic peritoneal mesothelioma is a rare disease. It is not certain if it is a benign or a borderline tumor. Although many therapeutic approaches have been used, complete cytoreductive surgery in combination with hyperthermic intraoperative intraperitoneal chemotherapy has gained acceptance. CASE REPORT: A case of multicystic peritoneal mesothelioma in a 16-year old patient is reported. The patient underwent complete cytoreduction and received intraoperative hyperthermic intraperitoneal chemotherapy. The patient is disease-free one year after surgery. CONCLUSIONS: Complete cytoreductive surgery in combination with hyperthermic intraoperative intraperitoneal chemotherapy appears to be a rational therapeutic approach in multicystic peritoneal mesothelioma.

5.
Gastroenterol Res Pract ; 2012: 506571, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22693491

RESUMO

Background and Aims. 5-year survival in patients with pancreatic cancer is poor. Surgical resection is the only potentially curative resection. The results of adjuvant treatment either with chemotherapy or with radiotherapy have been contradictory and the incidence of local-regional recurrence remains high. If local-regional recurrence is controlled survival may be expected to increase. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) may be used in order to control local-regional recurrences. The purpose of the study is to identify the effect of HIPEC in patients with pancreatic cancer undergoing potentially resection. Patients and Methods. From 2007-2011, 21 patients, mean age 69.4 ± 9.5 (50-86) years, underwent tumor resection, and HIPEC with gemcitabine. The hospital mortality and morbidity rate was 9.5% and 33.3%, respectively. 5-year and median survival was 23% and 11 months, respectively. The recurrence rate was 50% but no patient developed local-regional recurrence. No patient was recorded with gemcitabine-induced toxicity. Conclusions. This clinical study of 21 patients is the first to combine an R(0) pancreas cancer resection with HIPEC. Increased morbidity and mortality from intraoperative gemcitabine was not apparent. Patients with pancreatic cancer undergoing potentially curative resection in combination with HIPEC may be offered a survival benefit. Data suggested that local-regional recurrences may be greatly reduced. Further studies with greater number of patients are required to confirm these findings.

SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa